NOVARTIS AG

Drug Name	Phase	Indication	Designations	Patent
Imatinib	Phase 3	Chronic Myelogenous Leukemia in Chronic Phase	-	-
Darifenacin	Phase 3	Overactive Bladder Syndrome	-	-
capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)	Phase 3	Parkinson's Disease	-	-
Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine	Phase 3	Swine-Origin Influenza A H1N1 Virus	-	-
Canakinumab pre-filled syringe	Phase 3	Acute Gouty Arthritis	-	-
Vatalanib	Phase 3	Colorectal Neoplasms	-	-
Serogroup B meningococcal vaccine	Phase 3	Meningococcal Disease	-	-
rivastigmine transdermal patch	Phase 3	Alzheimer's Disease	-	-
Pasireotide	Phase 3	Cushing's Disease	-	-
Indacaterol 150 μg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Myfortic	Phase 3	Kidney Transplantation	-	-
amlodipine	Phase 3	Hypertension	-	-
Sunitinib	Phase 3	Carcinoma, Renal Cell	-	-
Umeclidinium/vilanterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Octreotide LAR	Phase 3	Acromegaly	-	-
Agomelatine (AGO178C)	Phase 3	Major Depressive Disorder	-	-
osilodrostat	Phase 3	Cushings Disease	-	-
Ofatumumab	Phase 3	Relapsing Multiple Sclerosis	-	-
Letrozole	Phase 3	Breast Cancer	-	-
LCZ696	Phase 3	Hypertension	-	-
Secukinumab (75 mg)	Phase 3	Psoriatic Arthritis	-	-
Diclofenac topical sodium gel 1%	Phase 3	Osteoarthritis	-	-
Pelabresib	Phase 3	Myelofibrosis	-	-
Ribociclib	Phase 3	Breast Cancer	-	-
Bortezomib	Phase 3	Multiple Myeloma	-	-
Meningococcal ACWY conjugate vaccine	Phase 3	Bacterial Meningitis	-	-
Fingolimod 1.25 mg	Phase 3	Multiple Sclerosis	-	-
sacubitril/valsartan	Phase 3	Heart Failure	-	-
TQJ230	Phase 3	Cardiovascular Disease and Lipoprotein(a)	-	-
Physicians' Choice	Phase 3	Leukaemia	-	-
ranibizumab 0.5mg	Phase 3	Choroidal Neovascularisation	-	-
Olmesartan	Phase 3	Essential Hypertension	-	-
Remibrutinib	Phase 3	Chronic Spontaneous Urticaria	-	-
Siponimod	Phase 3	Multiple Sclerosis (MS)	-	-
valsartan plus hydrochlorothiazide	Phase 3	Hypertension	-	-
oxcarbazepine	Phase 3	Epilepsy	-	-
RTH258/Brolucizumab	Phase 3	Neovascular Age Related Macular Degeneration	-	-
Formoterol (12 µg b.i.d.)	Phase 3	Pulmonary Disease, Chronic Obstructive	-	-
Adalimumab	Phase 3	Psoriatic Arthritis	-	-
Trametinib	Phase 3	Melanoma and Brain Metastases	-	-
Diclofenac sodium gel 1%	Phase 3	Osteoarthritis	-	-
zigakibart	Phase 3	Kidney Diseases	-	-
Pasireotide LAR	Phase 3	Acromegaly	-	-
Ranibizumab (RFB002)	Phase 3	Diabetic Macular Edema	-	-
Dabrafenib	Phase 3	Neoplasms, Brain	-	-
Nilotinib (AMN107)	Phase 3	Gastrointestinal Stromal Tumor (GIST)	-	-
RAD001	Phase 3	Carcinoma	-	-
Indacaterol 150 µg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
valsartan + amlodipine	Phase 3	Hypertension	-	-
NVA237	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
QAW039	Phase 3	Asthma	-	-
Ustekinumab	Phase 3	Psoriatic Arthritis	-	-
Lumiracoxib	Phase 3	Knee Osteoarthritis	-	-
Licarbazepine	Phase 3	Bipolar Disorder	-	-
Alcon Investigational Agent	Phase 3	Open-Angle Glaucoma	-	-
Anecortave Acetate 15 mg sterile suspension	Phase 3	Macular Degeneration	-	-
Gliclazide	Phase 3	Diabetes Mellitus, Type 2	-	-
Secukinumab 300 mg	Phase 3	Chronic Scalp Psoriasis	-	-
Salmeterol 50 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
EXE844 Sterile Otic Suspension, 0.3%	Phase 3	Otitis Media With Effusion in Children	-	-
Onasemnogene Abeparvovec-xioi	Phase 3	Spinal Muscular Atrophy Type I	-	-
Canakinumab	Phase 3	Rheumatoid Arthritis	-	-
Enteric-coated Mycophenolate sodium (EC-MPS)	Phase 3	Liver Transplantation	-	-
Artemether-lumefantrine	Phase 3	Plasmodium Falciparum Malaria	-	-
Prednisone	Phase 3	Renal Transplantation	-	-
AIN457	Phase 3	Plaque-type Psoriasis	-	-
goserelin	Phase 3	Advanced Metastatic Breast Cancer	-	-
Pelacarsen (TQJ230)	Phase 3	Cardiovascular Disease and Lipoprotein(a)	-	-
MF59-eH1N1_f	Phase 3	Influenza	-	-
Valsartan/amlodipine 80/5 mg	Phase 3	Hypertension	-	-
Valsartan	Phase 3	Hypertension	-	-
Nilotinib	Phase 3	Chronic Myelogenous Leukemia	-	-
iptacopan	Phase 3	IC-MPGN	-	-
rMenB+OMV NZ	Phase 3	Prevention of the Meningococcal Disease	-	-
FTY720	Phase 3	Multiple Sclerosis	-	-
Brolucizumab	Phase 3	Diabetic Macular Edema	-	-
Seasonal Influenza Vaccine	Phase 3	Influenza	-	-
valsartan/amlodipine	Phase 3	Hypertension	-	-
Panobinostat	Phase 3	Cutaneous T-Cell Lymphoma	-	-
Tiotropium 18 μg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Lapatinib	Phase 3	Breast Neoplasms	-	-
Fluvastatin	Phase 3	Mixed Dyslipidemia	-	-
Nepafenac Ophthalmic Suspension, 0.1%	Phase 3	Cataract	-	-
Inclisiran sodium 300 mg	Phase 3	Atherosclerotic Cardiovascular Disease	-	-
Haemophilus influenzae type b (Hib) vaccine	Phase 3	Haemophilus Influenzae Type b (Hib) Infection	-	-
NIS793	Phase 3	Metastatic Pancreatic Ductal Adenocarcinoma	-	-
Hydrochlorothiazide	Phase 3	Hypertension	-	-
Verteporfin Photodynamic Therapy	Phase 3	Macular Degeneration	-	-
MenACWY-CRM197	Phase 3	Meningitis	-	-
vildagliptin + metformin	Phase 3	Diabetes Mellitus, Type 2	-	-
Basiliximab	Phase 3	Liver Transplant	-	-
Indacaterol 300 µg	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
BION-1301	Phase 3	IgA Nephropathy	-	-
pioglitazone	Phase 3	Diabetes Mellitus, Type 2	-	-
LNP023	Phase 3	Paroxysmal Nocturnal Hemoglobinuria (PNH)	-	-
Ruxolitinib	Phase 3	Cytokine Storm (Covid-19)	-	-
Fulvestrant	Phase 3	Breast Cancer	-	-
eltrombopag	Phase 3	Immune Thrombocytopenic Purpura (ITP)	-	-
Ligelizumab	Phase 3	Chronic Spontaneous Urticaria	-	-
AMN107	Phase 3	Leukemia, Myeloid, Chronic	-	-
Erenumab	Phase 3	Episodic Migraine	-	-
QAB149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Tobramycin inhalation powder	Phase 3	Pulmonary Infections	-	-
LOU064	Phase 3	Chronic Spontaneous Urticaria	-	-
Bosutinib	Phase 3	Chronic Myelogenous Leukemia	-	-
LCZ696 (Sacubitril/Valsartan)	Phase 3	Chronic Heart Failure With Reduced Ejection Fraction	-	-
Metformin	Phase 3	Diabetes Mellitus, Type 2	-	-
agomelatine	Phase 3	Major Depressive Disorder (MDD)	-	-
Diclofenac Sodium	Phase 3	Acute Ankle Sprain	-	-
Influenza virus vaccine	Phase 3	Influenza	-	-
Everolimus	Phase 3	Tuberous Sclerosis	-	-
Famciclovir	Phase 3	Herpes Labialis	-	-
Certoparin	Phase 3	Renal Dialysis	-	-
Exemestane	Phase 3	Breast Cancer	-	-
Inclisiran	Phase 3	Atherosclerotic Cardiovascular Disease	-	-
Alpelisib	Phase 3	Breast Neoplasms	-	-
Glimepiride	Phase 3	Type II Diabetes Mellitus	-	-
ACZ885	Phase 3	Pulmonary Sarcoidosis	-	-
Glycopyrronium bromide	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Enalapril	Phase 3	Hypertension	-	-
asciminib	Phase 3	Chronic Myelogenous Leukemia - Chronic Phase	-	-
Paclitaxel	Phase 3	Breast Cancer	-	-
QVA149	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Everolimus (RAD001)	Phase 3	Renal Transplantation	-	-
Aflibercept	Phase 3	Diabetic Macular Edema	-	-
Salbutamol/albuterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
Lansoprazole	Phase 3	Frequent Heartburn	-	-
Aliskiren/HCTZ	Phase 3	Hypertension	-	-
vildagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
ranibizumab	Phase 3	Neovascular Age-related Macular Degeneration	-	-
Pimecrolimus Cream 1%	Phase 3	Chronic Hand Dermatitis	-	-
secukinumab 150 mg	Phase 3	Moderate to Severe Chronic Plaque-type Psoriasis	-	-
Telbivudine (LdT)	Phase 3	Chronic Hepatitis B	-	-
TIVc	Phase 3	Influenza	-	-
Rivastigmine	Phase 3	Vascular Dementia	-	-
VAY736	Phase 3	Sjogren Syndrome	-	-
Certican	Phase 3	Kidney Transplantation	-	-
Vildagliptin AM	Phase 3	Diabetes Mellitus, Type 2	-	-
Omalizumab	Phase 3	Asthma	-	-
QVM149	Phase 3	Asthma	-	-
secukinumab	Phase 3	Juvenile Psoriatic Arthritis	-	-
terbinafine	Phase 3	Onychomycosis	-	-
Sitagliptin	Phase 3	Diabetes Mellitus, Type 2	-	-
Tegaserod	Phase 3	Dyspepsia	-	-
Monovalent A/H1N1 influenza vaccine	Phase 3	Pandemic Influenza	-	-
Tisagenlecleucel	Phase 3	Follicular Lymphoma (FL)	-	-
aliskiren	Phase 3	Hypertension	-	-
CTL019	Phase 3	Acute Lymphoblastic Leukemia	-	-
imatinib mesylate	Phase 3	Leukemia	-	-
Indacaterol 300 μg	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
deferasirox	Phase 3	Non-transfusion Dependent Thalassemia	-	-
Ranibizumab 0.5 mg	Phase 3	Proliferative Diabetic Retinopathy (PDR)	-	-
telbivudine	Phase 3	Chronic Hepatitis B	-	-
Meningococcal C Conjugate Vaccine	Phase 3	Prevention of Meningococcal Infection	-	-
Formoterol	Phase 3	Chronic Obstructive Pulmonary Disease	-	-
RLX030	Phase 3	Acute Heart Failure	-	-
Fingolimod	Phase 3	Multiple Sclerosis	-	-
secukinumab (AIN457)	Phase 3	Rheumatoid Arthritis	-	-
Ianalumab	Phase 3	Primary Immune Thrombocytopenia (ITP)	-	-
Indacaterol	Phase 3	Asthma	-	-
Zoledronic acid	Phase 3	Breast Cancer With Bone Metastasis	-	-
Mycophenolate mofetil (MMF)	Phase 3	Kidney Transplantation	-	-
Tiotropium	Phase 3	Chronic Obstructive Pulmonary Disease (COPD)	-	-
Olmesartan medoxomil	Phase 3	Hypertension	-	-
Tacrolimus	Phase 3	Kidney Diseases	-	-
ramipril	Phase 3	Heart Failure	-	-
inclisiran sodium	Phase 3	Hypercholesterolemia	-	-
Tamoxifen	Phase 3	Hormone Sensitive Resected Primary Breast Cancer in Postmenopausal Women	-	-
trivalent split influenza vaccine	Phase 3	Seasonal Influenza	-	-
dovitinib	Phase 3	Solid Tumors	-	-
Focalin XR	Phase 3	ADHD	-	-
Anastrozole	Phase 3	Breast Cancer	-	-
Everolimus + reduced tacrolimus	Phase 3	Liver Transplantation	-	-
Octreotide	Phase 3	Acromegaly	-	-
Pelacarsen	Phase 3	Atherosclerotic Cardiovascular Disease (ASCVD)	-	-
rMenB+OMV	Phase 3	Meningococcal Disease	-	-
Lamivudine	Phase 3	Chronic Hepatitis B	-	-
ciclosporin	Phase 3	Severe Atopic Dermatitis	-	-
Enteric-Coated Mycophenolate Sodium	Phase 3	Prevention of Acute Rejection After Kidney Transplantation	-	-
Mycophenolate sodium (enteric coated)	Phase 3	Renal Transplant	-	-
Pazopanib	Phase 3	Ovarian Cancer	-	-
Pimecrolimus	Phase 3	Keratoconjunctivitis Sicca	-	-
MenACWY-CRM	Phase 3	Meningococcal Disease	-	-
LCQ908	Phase 3	Familial Chylomicronemia Syndrome (FCS)	-	-
TIV	Phase 2	Human Influenza	-	-
Investigator choice of chemotherapy	Phase 2	Nasopharyngeal Carcinoma	-	-
Sandostatin LAR Depot	Phase 2	Primary Insulin Hypersecretion	-	-
LFG316	Phase 2	Neovascular Age-elated Macular Degeneration (Wet AMD)	-	-
Hydrochlorothiazide (HCTZ)	Phase 2	Essential Hypertension	-	-
inhaled corticosteroid therapy	Phase 2	Bronchial Asthma	-	-
Midostaurin	Phase 2	Acute Myeloid Leukemia	-	-
Iptacopan (LNP023)	Phase 2	Age-Related Macular Degeneration	-	-
Nidufexor	Phase 2	Diabetic Nephropathy	-	-
DNK333 5 mg	Phase 2	Pruritus in Patients With Atopic Dermatitis	-	-
ECMPS-IEM	Phase 2	Detection Accuracy	-	-
LYS006 20 mg	Phase 2	Inflammatory Acne	-	-
AEE788	Phase 2	Glioblastoma Multiforme	-	-
Clozapine	Phase 2	Schizophrenia	-	-
prednisolone	Phase 2	Healthy	-	-
QMF149	Phase 2	COPD	-	-
Cyclosporine	Phase 2	Severe Aplastic Anemia	-	-
Trivalent influenza virus vaccine (TIV)	Phase 2	Human Influenza	-	-
LDK378	Phase 2	Non-Small-Cell Lung Cancer	-	-
Serelaxin	Phase 2	Acute Heart Failure	-	-
LIK066	Phase 2	Polycystic Ovary Syndrome	-	-
LEE011	Phase 2	Tumors With CDK4/6 Pathway Activation	-	-
CMK389	Phase 2	Pulmonary Sarcoidosis	-	-
crizanlizumab	Phase 2	Sickle Cell Disease (SCD)	-	-
Bendamustine	Phase 2	Chronic Lymphocytic Leukemia (CLL)	-	-
Mometasone furoate	Phase 2	Asthma	-	-
Seasonal flu vaccine	Phase 2	Seasonal Influenza	-	-
Atrasentan	Phase 2	IgA Nephropathy	-	-
AFQ056	Phase 2	Dyskinesias	-	-
TIN816 70 mg lyophilisate powder	Phase 2	Acute Kidney Injury Due to Sepsis	-	-
epothilone b	Phase 2	Colorectal Neoplasms	-	-
JDQ443	Phase 2	Locally Advanced or Metastatic KRAS G12C-mutated NSCLC With a PD-L1 Expression <1% or a PD-L1 Expression ≥ 1% and an STK11 Co-mutation	-	-
AUY922	Phase 2	Relapsed or Refractory Multiple Myeloma	-	-
[177Lu]Lu-PSMA-617	Phase 2	Metastatic Castration-Resistant Prostate Cancer (mCRPC)	-	-
LAG525	Phase 2	Melanoma	-	-
QGE031	Phase 2	Asthma	-	-
BGG492	Phase 2	Adrenocortical Adenoma	-	-
rMenB	Phase 2	Meningococcal Disease	-	-
AIN457A	Phase 2	Psoriatic Arthritis	-	-
Crizanlizuamb	Phase 2	Sickle Cell Disease (SCD)	-	-
PDR001	Phase 2	Small Cell Lung Cancer	-	-
VHB937	Phase 2	Alzheimer's Disease	-	-
Adjuvanted H5N1 pandemic influenza vaccine	Phase 2	Pandemic H5N1 Influenza	-	-
indacaterol/glycopyrrolate	Phase 2	Chronic Obstructive Pulmonary Disease (COPD)	-	-
SAF312	Phase 2	Chronic Ocular Pain	-	-
Adjuvanted influenza vaccine	Phase 2	Influenza Disease	-	-
BAF312	Phase 2	Relapsing Remitting Multiple Sclerosis	-	-
MAS825	Phase 2	Coronary Heart Disease	-	-
MCS110	Phase 2	Triple Negative Breast Cancer	-	-
influenza vaccine	Phase 2	Influenza	-	-
LCI699	Phase 2	Hypertension	-	-
AQW051	Phase 2	Schizophrenia	-	-
DFV890	Phase 2	Symptomatic Knee Osteoarthritis	-	-
TCH346	Phase 2	Amyotrophic Lateral Sclerosis	-	-
DNK333	Phase 2	Irritable Bowel Syndrome	-	-
LDE225	Phase 2	Medulloblastoma	-	-
AEB071	Phase 2	Kidney Transplantation	-	-
CDZ173	Phase 2	Primary Sjögren's Syndrome	-	-
AAE581	Phase 2	Osteoporosis	-	-
Monovalent inactivated influenza vaccine	Phase 2	Prepandemic Influenza Vaccine	-	-
Triamcinolone acetonide	Phase 2	Acute Gout	-	-
PKN605	Phase 2	Atrial Fibrillation	-	-
rapcabtagene autoleucel (YTB323)	Phase 2	Relapsing Multiple Sclerosis	-	-
dexamethasone	Phase 2	Arthritis, Gouty	-	-
YTB323	Phase 2	Systemic Lupus Erythematosus	-	-
ICL670	Phase 2	Sickle Cell Disease	-	-
KAE609	Phase 2	Malaria	-	-
BYM338	Phase 2	Sporadic Inclusion Body Myositis	-	-
CJM112	Phase 2	Asthma	-	-
CFZ533	Phase 2	Sjögren Syndrome	-	-
Capmatinib	Phase 2	Non-Small Cell Lung Cancer (NSCLC)	-	-
Salmeterol	Phase 2	Asthma	-	-
LYS006	Phase 2	Hidradenitis Suppurativa	-	-
QAX576	Phase 2	Allergic Rhinitis	-	-
Cryptosporidium parvum oocysts (ABO809)	Phase 2	Cryptosporidiosis	-	-
HSC835	Phase 2	Single Umbilical Cord Blood Transplantation	-	-
rapcabtagene autoleucel	Phase 2	Lupus Erythematosus, Systemic	-	-
cetuximab	Phase 2	KRAS G12C Mutant Solid Tumors	-	-
Vinorelbine	Phase 2	Cancer	-	-
LDE225 0.25%	Phase 2	Treatment for Basal Cell Carcinomas (BCCs) in Gorlin Syndrome Patients	-	-
N-acetylcysteine	Phase 2	Common Cold Associated With Cough	-	-
buparlisib	Phase 2	Breast Cancer	-	-
H5N1 influenza vaccine	Phase 2	Avian Influenza	-	-
bimagrumab	Phase 2	Muscle Wasting (Atrophy) After Hip Fracture Surgery	-	-
SBR759	Phase 2	Chronic Kidney Disease	-	-
Surface Antigen, Inactivated, Influenza (form.2006-07)	Phase 2	Influenza	-	-
BKM120	Phase 2	HER2-positive Newly Diagnosed, Primary Breast Cancer	-	-
GIA632	Phase 2	Non-segmental Vitiligo	-	-
Patupilone	Phase 2	Hepatocellular Carcinoma	-	-
LHW090	Phase 2	Chronic Kidney Disease (CKD)	-	-
Aliskiren 300 mg	Phase 2	Post Acute Coronary Syndrome	-	-
Spartalizumab	Phase 2	Advanced Hepatocellular Carcinoma	-	-
INC424	Phase 2	Primary Myelofibrosis	-	-
Capecitabine	Phase 2	Breast Cancer	-	-
Eltrombopag 12.5 mg	Phase 2	Cytopaenia	-	-
CAD106	Phase 2	Alzheimer Disease	-	-
fluticasone propionate/salmeterol	Phase 2	Asthma	-	-
AHU377	Phase 2	Systolic Hypertension	-	-
Investigational Treatment	Phase 2	Actinic Keratosis	-	-
Deferasirox (ICL670)	Phase 2	Iron Overload	-	-
Dovitinib (TKI258)	Phase 2	Gastrointestinal Stromal Tumors	-	-
QBW251	Phase 2	Chronic Obstructive Pulmonary Disease, COPD	-	-
TKI258	Phase 2	Melanoma	-	-
Investigational new drug, company code: BGG492	Phase 2	Seizures	-	-
Montelukast	Phase 2	Allergic Rhinitis	-	-

Catalyst Verdict

Market-Implied Move

Regulatory Approvals

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

NOVARTIS AG

Market Overview

NVSEF News

Catalyst Timeline

Pipeline & FDA Submissions

AI Predictions & Institutional Flow

Market Intelligence

Regulatory Approvals